https://www.selleckchem.com/pr....oducts/pacap-1-38.ht
The additive benefit of interleukin-2 receptor antagonist (IL2-RA) induction in standard-risk kidney transplant recipients, while maintained on tacrolimus-based immunosuppressive therapy, is uncertain. We divided the studies included in this meta-analysis into 2 groups group A (included studies that used same dose of tacrolimus in both arms of each study) and group B (included studies that compared patients who received induction therapy and low-dose tacrolimus vs. those who received no-induction therapy and high dose of tacrolimus).
Curtir
Comentario
Compartilhar
